Plasma miR-185 as a predictive biomarker for prognosis of malignant glioma
Plasma miR-185 as a predictive biomarker for prognosis of malignant glioma
复制标题
血浆 miR-185 作为恶性神经胶质瘤预后的预测生物标志物。
DOI：
10.4103/0973-1482.146121
复制
发表时间：
2015-07-01
影响因子：
1.3
通讯作者：
Wu, Minghua
中科院分区：
文献类型：
--
作者：
Tang, Hailin;Liu, Qing;Wu, Minghua
导读：在多种人类癌症中已经发现了特定的microRNA （miRNA）表达特征。最近，越来越多的证据表明，mirna存在于人的血清和血浆中。材料与方法：采用定量逆转录酶聚合酶链反应测定66例胶质瘤患者、11例垂体腺瘤患者、32例脑膜瘤患者和14例听神经瘤患者血浆中miR-185的水平。结果：与正常对照相比，胶质瘤患者血浆中miR-185水平显著改变。然而，在脑膜瘤、听神经瘤或垂体腺瘤等其他脑肿瘤患者中，其水平没有明显变化。此外，在手术和化疗放疗的多形性胶质母细胞瘤患者中，miR-185的血浆水平几乎恢复到正常水平。最后，我们还证明了低血浆miR-185水平与胶质瘤患者的低生存率相关。结论：这些发现表明血浆miR-185已成为胶质瘤的潜在生物标志物，并可能在胶质瘤患者的临床管理中有用。
Introduction: Specific microRNA (miRNA) expression signatures have been identified in a variety of human cancers. More recently, increasing evidence shows that miRNAs exist in human blood serum and plasma.Materials and Methods: Levels of miR-185 in plasma were measured by quantitative reverse-transcriptase polymerase chain reaction in 66 glioma patients, 11 pituitary adenoma patients, 32 meningioma patients, and 14 acoustic neuroma patients.Results: The plasma levels of miR-185 were significantly altered in glioma patients compared to normal controls. However, its levels were not observably changed in patients with other brain tumors such as meningioma, acoustic neuroma, or pituitary adenoma. Furthermore, the plasma levels of miR-185 in glioblastoma multiforme patients with operation and chemo-radiation almost revived to normal levels. Finally, we also demonstrated that low plasma miR-185 levels are correlated with poor survival in glioma patients.Conclusion: These findings suggest that plasma miR-185 has become potential biomarkers for glioma and may be useful in clinical management for glioma patients.